LinkedIn
WebsiteIntroduction
ENDRA Life Sciences Inc. (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies based in Ann Arbor, Michigan. The company’s Thermo-Acoustic Enhanced UltraSound (TAEUS®) platform is designed to provide information on tissue composition, function, and temperature comparable to that obtained through biopsy and MRI, while being significantly lower in cost. TAEUS’s initial clinical focus is the quantification of liver fat to assess Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), conditions that affect more than two billion people globally.
As of October 13, 2023, ENDRA’s shares closed at $9.8536, reflecting a 52.06% increase on the day, with a trading volume of 4,103,928 shares. The company is listed on the NASDAQ under the ticker symbol NDRA.
Corporate Structure
Founded on July 18, 2007, ENDRA employs between 11 and 50 people, including engineers, healthcare professionals, and commercial leaders. The company operates a Quality Management System certified to ISO 13485:2016 and EN ISO 13485:2016 (Certificate No. MD 697226), effective from April 2, 2025, through April 1, 2028.
ENDRA’s leadership team possesses experience in medical imaging, device development, and regulatory affairs. The company collaborates with leading medical researchers and equipment manufacturers to facilitate the clinical deployment of TAEUS.
Ultrasound Technology by National Cancer Institute
Developments and News
ENDRA’s ISO 13485:2016 certification became effective on April 2, 2025, ensuring compliance with international standards for medical device quality management. The company’s Investor Relations overview noted advancements in its next-generation TAEUS system, which is intended to enable clinicians to assess human tissue biomarkers at the point of care. In addition to liver-fat quantification, ENDRA is exploring applications for monitoring tissue temperature during energy-based surgical procedures.
Discussions are ongoing with ultrasound system manufacturers to integrate TAEUS with the estimated one million ultrasound units currently in use globally. A statement from GE Healthcare referenced ENDRA’s potential to enhance access to affordable healthcare.
Financial and Strategic Analysis
ENDRA Life Sciences has not disclosed total revenue figures for fiscal year 2024. According to CNN Markets data, the company recorded a net loss of $11.51 million for the twelve months ended June 30, 2025, and $1.23 million for the quarter ended June 30, 2025. Earnings per share were reported as negative $56.94 for the one-year period and negative $1.71 for the quarter, indicating sequential growth of 8.02%.
Strategically, ENDRA’s TAEUS platform aims to address a significant diagnostic gap in the management of NAFLD and NASH, where current diagnostic tools—MRI and invasive biopsy—are often not practical for routine screening. By targeting a market opportunity related to metabolic disease detection, GLP-1 drug eligibility, and noninvasive monitoring, ENDRA seeks to establish key biomarkers for conditions that significantly impact global health expenditures.
Market Position and Industry Context
Within the Health Technology sector and Medical Specialties group, ENDRA competes indirectly with providers of MRI and biopsy services rather than with traditional ultrasound vendors. Its market capitalization of approximately $4.88 million places it within the category of smaller-cap medical device companies.
ENDRA’s value proposition includes:
- Cost efficiency: TAEUS is noted to be significantly less expensive compared to CT or MRI.
- Point-of-care deployment: Compatibility with existing ultrasound technology.
- Clinical relevance: Focus on NAFLD/NASH, conditions projected to be the leading cause of liver transplants by 2025.
The lack of practical, noninvasive diagnostic tools for fatty liver disease presents an opportunity for TAEUS to gain market share, especially as the demand for metabolic disease management tools continues to rise.
tl;dr
On October 13, 2023, ENDRA’s stock increased by 52.06% to $9.8536, driven by investor interest in its TAEUS platform designed for noninvasive liver-fat quantification. The company’s ISO 13485 certification became effective on April 2, 2025, valid through April 1, 2028. ENDRA reported net losses of $11.51 million for the year ended June 30, 2025, and continues efforts to integrate TAEUS with existing ultrasound systems, aiming to enhance clinical applications, including metabolic-disease detection and surgical-temperature monitoring. Future goals will focus on the commercialization of its device for widespread adoption in point-of-care settings.
